Definium Therapeutics, Inc. (DFTX) Stock Forecast
DFTX analyst forecast
as of October 18, 2026- Analyst consensus
- Strong buy 4.74 / 5 from 19 analysts
- Price target
- $72.33 average of analyst targets
- Upside to target
- +125.3% from the latest close
- Next earnings
- November 5, 2026 EPS estimate $-0.55
- 52-week range
- $10.68 – $48.45
DFTX analyst ratings
19 analystsNumber of analysts at each rating.
DFTX price target
The average of analyst 12-month price targets compared with the latest close and the 52-week range.
DFTX earnings per share estimates
| Period | Average | Low | High | Year ago | Growth | Analysts |
|---|---|---|---|---|---|---|
| Current quarter (Sep '26) | −$0.56 | −$0.70 | −$0.45 | −$0.78 | +28.1% | 14 |
| Current fiscal year (2026) | −$3.18 | −$3.59 | −$2.93 | −$2.06 | −54.4% | 15 |
| Next fiscal year (2027) | −$1.94 | −$4.16 | $0.05 | −$3.18 | +39.0% | 14 |
Consensus EPS estimates; growth compares the average estimate with the year-ago EPS.
DFTX revenue estimates
| Period | Average | Low | High | Growth | Analysts |
|---|---|---|---|---|---|
| Current quarter (Sep '26) | $0 | $0 | $0 | 0.0% | 16 |
| Current fiscal year (2026) | $0 | $0 | $0 | 0.0% | 16 |
| Next fiscal year (2027) | $29.3M | $0 | $317.5M | 0.0% | 15 |
DFTX EPS: reported and forecast
Fiscal years; "E" marks estimates, the line shows the range from the lowest to the highest estimate.
DFTX revenue: reported and forecast
DFTX EPS estimate revisions
| Period | 90 days ago | 60 days ago | 30 days ago | 7 days ago | Now | Change (90 d) | Revisions (30 d) |
|---|---|---|---|---|---|---|---|
| Current quarter (Sep '26) | −$0.54 | −$0.53 | −$0.56 | −$0.56 | −$0.56 | +4.7% | 1 up · 0 down |
| Current fiscal year (2026) | −$2.23 | −$2.98 | −$3.16 | −$3.16 | −$3.18 | +42.5% | 2 up · 0 down |
| Next fiscal year (2027) | −$1.51 | −$1.70 | −$1.88 | −$1.90 | −$1.94 | +28.4% | 0 up · 1 down |
How the consensus EPS estimate changed over the last 90 days, and how many analysts raised or lowered it in the last 30 days.
DFTX earnings surprises
Reported EPS vs the consensus estimate for the last 12 quarters; DFTX beat in 5 of 12.
What analysts expect from DFTX
19 analysts cover Definium Therapeutics; their consensus rating is strong buy (4.74 on a 1–5 scale, where 5 is a strong buy). The average price target is $72.33, 125.3% above the latest close of $32.10. Analysts expect earnings of −$3.18 per share for 2026, −54.4% from a year earlier. For 2027 the average estimate is −$1.94 per share on revenue of $29.3 million. Definium Therapeutics beat the EPS estimate in 5 of the last 12 quarters.
Related: DFTX income statement, DFTX key metrics, DFTX chart. See the DFTX stock overview for the latest quote and news.
DFTX forecast FAQ
What is Definium Therapeutics's price target?
The average analyst price target for Definium Therapeutics is $72.33, 125.3% above the latest close of $32.10.
Is Definium Therapeutics a buy, hold or sell?
Of 19 analysts covering Definium Therapeutics, 14 rate it a strong buy, 5 a buy, 0 a hold, 0 a sell and 0 a strong sell, a consensus of strong buy. Ratings are opinions, not a recommendation from Quotelinks.
What is Definium Therapeutics's EPS forecast?
Analysts forecast −$3.18 per share for 2026 (range −$3.59 to −$2.93); for 2027 the estimate is −$1.94.
When does Definium Therapeutics report earnings?
Definium Therapeutics is expected to report results for the quarter ending September 30, 2026 on November 5, 2026 after the market closes; the EPS estimate is $-0.55.
Does Definium Therapeutics usually beat earnings estimates?
Definium Therapeutics reported EPS at or above the analyst estimate in 5 of the last 12 quarters.